These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33063185)

  • 1. Prospective study of Lipiodol distribution as an imaging marker for doxorubicin pharmacokinetics during conventional transarterial chemoembolization of liver malignancies.
    Savic LJ; Chapiro J; Funai E; Bousabarah K; Schobert IT; Isufi E; Geschwind JH; Stark S; He P; Rudek MA; Perez Lozada JC; Ayyagari R; Pollak J; Schlachter T
    Eur Radiol; 2021 May; 31(5):3002-3014. PubMed ID: 33063185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial.
    Letzen BS; Malpani R; Miszczuk M; de Ruiter QMB; Petty CW; Rexha I; Nezami N; Laage-Gaupp F; Lin M; Schlachter TR; Chapiro J
    Clin Imaging; 2021 Oct; 78():194-200. PubMed ID: 34022765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer.
    Stark S; Wang C; Savic LJ; Letzen B; Schobert I; Miszczuk M; Murali N; Oestmann P; Gebauer B; Lin M; Duncan J; Schlachter T; Chapiro J
    Sci Rep; 2020 Oct; 10(1):18026. PubMed ID: 33093524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
    Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
    Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
    van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
    Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
    Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
    Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of drug release and pharmacokinetics after transarterial chemoembolization using diverse lipiodol emulsions and drug-eluting beads.
    Choi JW; Cho HJ; Park JH; Baek SY; Chung JW; Kim DD; Kim HC
    PLoS One; 2014; 9(12):e115898. PubMed ID: 25551760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.
    Gaba RC; Khabbaz RC; Muchiri RN; Morrison JD; Elkhadragy L; Totura WM; Samuelson JP; Whiteley HE; Deaton RL; Nguyen PL; Sverdlov M; Johnson JJ; van Breemen RB; Lokken RP
    Drug Deliv Transl Res; 2022 May; 12(5):1105-1117. PubMed ID: 33861419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical Shift MRI Monitoring of Chemoembolization Delivery for Hepatocellular Carcinoma: Multicenter Feasibility of Initial Clinical Translation.
    Gordon AC; Lewandowski RJ; Li W; Zhong X; Kannengiesser SAR; Miller FH; Salem R; Rilling WS; Larson AC; White SB
    Radiol Imaging Cancer; 2023 May; 5(3):e220019. PubMed ID: 37233207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response assessment methods for patients with hepatic metastasis from rare tumor primaries undergoing transarterial chemoembolization.
    Adam LC; Savic LJ; Chapiro J; Letzen B; Lin M; Georgiades C; Hong KK; Nezami N
    Clin Imaging; 2022 Sep; 89():112-119. PubMed ID: 35777239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma.
    Lilienberg E; Dubbelboer IR; Karalli A; Axelsson R; Brismar TB; Ebeling Barbier C; Norén A; Duraj F; Hedeland M; Bondesson U; Sjögren E; Stål P; Nyman R; Lennernäs H
    Mol Pharm; 2017 Feb; 14(2):448-458. PubMed ID: 27997198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit livers.
    Zhang S; Huang C; Li Z; Yang Y; Bao T; Chen H; Zou Y; Song L
    Drug Deliv; 2017 Nov; 24(1):1011-1017. PubMed ID: 28660787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipiodol retention pattern assessed by cone beam computed tomography during conventional transarterial chemoembolization of hepatocellular carcinoma: accuracy and correlation with response.
    Hu J; Maybody M; Cao G; Wang X; Chen H; Zhu X; Yang R; Wang X
    Cancer Imaging; 2016 Oct; 16(1):32. PubMed ID: 27716376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periodic mesoporous organosilica-coated magnetite nanoparticles combined with lipiodol for transcatheter arterial chemoembolization to inhibit the progression of liver cancer.
    Liu L; Xu X; Liang X; Zhang X; Wen J; Chen K; Su X; Ma Y; Teng Z; Lu G; Xu J
    J Colloid Interface Sci; 2021 Jun; 591():211-220. PubMed ID: 33609893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
    Wang Z; Chen R; Duran R; Zhao Y; Yenokyan G; Chapiro J; Schernthaner R; Radaelli A; Lin M; Geschwind JF
    Cardiovasc Intervent Radiol; 2015 Dec; 38(6):1548-56. PubMed ID: 26001366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE).
    Wiggermann P; Sieron D; Brosche C; Brauer T; Scheer F; Platzek I; Wawrzynek W; Stroszczynski C
    Med Sci Monit; 2011 Apr; 17(4):CR189-95. PubMed ID: 21455104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early prediction of 1-year tumor response of hepatocellular carcinoma with lipiodol deposition pattern through post-embolization cone-beam computed tomography during conventional transarterial chemoembolization.
    Tsai YC; Shih JH; Hwang HE; Chiu NC; Lee RC; Tseng HS; Liu CA
    Eur Radiol; 2021 Oct; 31(10):7464-7475. PubMed ID: 33765160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipiodol as a Predictive Indicator for Therapy Response to Transarterial Chemoembolization of Hepatocellular Carcinoma.
    Langenbach MC; Vogl TJ; Said G; Scholtz JE; Hammerstingl R; Gruber-Rouh T
    Cancer Biother Radiopharm; 2024 Apr; 39(3):196-202. PubMed ID: 33481646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.